Phase 3 study (TRIUMPH-5), condition: Obesity. The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks. Enrolment: 800 participants. Status: active, not recruiting. No topline or peer-reviewed results are verified for publication on this Record for this study — registry facts only.
Checked 2026-08-08 · next review due 2026-11-08
← Back to the Record